Many of the recent advancements in the area of tumor immunobiology have allowed us to focus our efforts on the experimental treatment of patients with metastatic melanoma. It has been both a frustrating and often a seemingly futile effort on the parts of physicians and researchers alike in treating such patients. The last decade of research has resulted in a paradigm shift in our understanding of the immunologic interactions between a tumor cell and the host immune response. The discovery and clinical application of tumor-associated antigens has allowed for a selective and highly specific approach to the treatment of patients with stage IV metastatic melanoma (1 ).
